Duncan, CJA,Mohamad, SMB,Young, DF,Skelton, AJ,Leahy, TR,Munday, DC,Butler, KM,Morfopoulou, S,Brown, JR,Hubank, M,Connell, J,Gavin, PJ,McMahon, C,Dempsey, E,Lynch, NE,Jacques, TS,Valappil, M,Cant, AJ,Breuer, J,Engelhardt, KR,Randall, RE,Hambleton, S

2015

September

Science Translational Medicine

Human IFNAR2 deficiency: Lessons for antiviral immunity

Validated

Altmetric: 18 ()

PYOGENIC BACTERIAL-INFECTIONS TARGETED DISRUPTION ILLUMINA MICROARRAY VIRAL DISEASE MEASLES-VIRUS INTERFERON INDUCTION MICE ENCEPHALITIS INNATE

7

Type I interferon (IFN-alpha/beta) is a fundamental antiviral defense mechanism. Mouse models have been pivotal to understanding the role of IFN-alpha/beta in immunity, although validation of these findings in humans has been limited. We investigated a previously healthy child with fatal encephalitis after inoculation of the live attenuated measles, mumps, and rubella (MMR) vaccine. By targeted resequencing, we identified a homozygous mutation in the high-affinity IFN-alpha/beta receptor (IFNAR2) in the proband, as well as a newborn sibling, that rendered cells unresponsive to IFN-alpha/beta. Reconstitution of the proband's cells with wild-type IFNAR2 restored IFN-alpha/beta responsiveness and control of IFN-attenuated viruses. Despite the severe outcome of systemic live vaccine challenge, the proband had previously shown no evidence of heightened susceptibility to respiratory viral pathogens. The phenotype of IFNAR2 deficiency, together with similar findings in STAT2-deficient patients, supports an essential but narrow role for IFN-alpha/beta in human antiviral immunity.

10.1126/scitranslmed.aac4227